GLO1 Antibody

說明書

中文名稱：

GLO1兔多克隆抗體
貨號：

CSB-PA871864DSR1HU
規格：

￥440
圖片：
Western blot
All lanes: GLO1 antibody at 2μg/ml
Lane 1: HepG2 whole cell lysate
Lane 2: Hela whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 21, 20 kDa
Observed band size: 21 kDa

Immunohistochemistry of paraffin-embedded human prostate tissue using CSB-PA871864DSR1HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) GLO1 Polyclonal antibody
Uniprot No.：

Q04760
基因名：

GLO1
別名：

Aldoketomutase antibody; glo1 antibody; GLOD1 antibody; Glx I antibody; GLYI antibody; glyoxalase domain containing 1 antibody; Glyoxalase I antibody; Ketone aldehyde mutase antibody; Ketone-aldehyde mutase antibody; Lactoyl glutathione lyase antibody; Lactoylglutathione lyase antibody; LGUL_HUMAN antibody; Methylglyoxalase antibody; S D lactoylglutathione methylglyoxal lyase antibody; S-D-lactoylglutathione methylglyoxal lyase antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Lactoylglutathione lyase protein (1-184AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:200-1:1000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Required for normal osteoclastogenesis.
基因功能參考文獻：
1. GLO1 SNPs, rs1130534 (c.372A>T, p.G124G), rs2736654 (c.A332C, p.E111A) and rs1049346 (c.-7C>T, 5'-UTR) were genotyped. While c.A332C polymorphism was not associated with retinitis pigmentosa (RP), c.372A>T showed an allelic association. Conversely, c.-7C>T showed both genotypic and allelic associations. RP susceptibility may be associated with two of the analyzed GLO1 polymorphisms (rs1130534 and rs1049346). PMID: 30099685
2. The active sites of human and staphylococcus glyoxalases I are also different: the former contains one Zn-ion per chain; the latter incorporates two of these ions.. We suggest that only single Zn1-ion plays the role of catalytic center. The newly found differences between the two subfamilies could guide the design of new drugs against S. aureus, an important pathogenic micro-organism. PMID: 28034013
3. This study shows that only the GLO1 C-7T polymorphism, and not the GLO1 A419C and ALR C-106T polymorphisms, is associated with carotid atherosclerosis in Chinese patients with type 2 diabetes. PMID: 21294693
4. The expression of glyoxalase system member glyoxalase 1 (GLO1) in melanoma cells is downregulated by miR-137. siRNA targeting of GLO1 mimicks inhibition of melanoma cell proliferation caused by miR-137 overexpression. Re-expression of GLO1 restores miR-137-mediated suppression of melanoma cell proliferation. PMID: 29307109
5. The critical role of glyoxalases as regulators of tumorigenesis in the prostate through modulation of various critical signaling pathways, and an overview of the current knowledge on glyoxalases in bladder, kidney and testis cancers is reviewed.(GLO1, GLO2) PMID: 29385039
6. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models PMID: 29385725
7. current research highlighted the Glo-I/AGE/RAGE system as an interesting therapeutic target in chronic liver diseases. These findings need further elucidation in preclinical and clinical studies. PMID: 29156655
8. GLO1-knockdown provoked collagen expression, endothelial inflammation and dysfunction and apoptosis which might contribute to vascular damage PMID: 27898103
9. expressed in basal epidermis; significantly higher expression in older individuals PMID: 26914966
10. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells. PMID: 29225125
11. Induced Glyoxalase 1 expression is a common feature in the pathogenesis of oropharyngeal squamous cell carcinoma PMID: 28549423
12. The lowering of glycative stress via modulation of RAGE-AGE axis or glyoxalase 1 activity is beneficial for tubular homeostasis and the subsequent prevention and treatment of kidney disease, suggesting the possibility of novel therapeutic approaches which target glycative stress. PMID: 27270765
13. Glo-1 responds to dicarbonyl stress to enhance cytoprotection at the transcriptional level through stress-responsive increase of Glo-1 expression. PMID: 27406712
14. Glo1, together with Glo2, represents a novel mechanism in prostate cancer progression driven by a PTEN/PI3K/AKT/mTOR signaling pathway. PMID: 27696457
15. Gly82Ser and 2184 A/G RAGE polymorphisms were related to the mortality due to the breast cancer and -419 A/C glyoxalase I polymorphism was related to the overall mortality of the patients suggesting their role not only in the risk of breast cancer but also in the outcome of patients with breast cancer. PMID: 28695773
16. Reduction of GLO1 activity in atherosclerotic lesions of nondiabetic patients with increased HbA1c is associated with a functional involvement of this protective enzyme in atherogenesis. PMID: 27478003
17. Studies suggest that the enhancement of glyoxalase I (GLO-1) is a promising strategy aimed at halting the vicious cycle between chronic kidney disease and increases in glycative stress. PMID: 28106734
18. GLO1 on one hand is crucial to maintaining tumor characteristics of malignant cells, and, on the other hand, supports malignant transformation of cells in a hypoxic environment when overexpressed. PMID: 27999356
19. GLO1 SNPs are significantly associated with late-onset and drug-resistant epilepsy. PMID: 27000251
20. MS5 induced hydrogen peroxide-mediated c-Jun-dependent Glo1 up-regulation which resulted in a decrease in the Argpyrimidine-modified Hsp70 protein level which triggered EMT in a novel mechanism involving miR-21 and SMAD signalling PMID: 26784015
21. MMP-9 and Bcl-2 expression levels were dramatically decreased by addition of methylglyoxal or inhibition of GLOI. These findings may provide a new approach for the treatment of breast cancer. PMID: 26618552
22. Data suggest Glo1's effects on anxiety-like behavior are centrally mediated as overexpression of Glo1 in neurons was sufficient to increase anxiety-like behavior PMID: 26711908
23. Studies indicate that the most extensively investigated The most extensively investigated glyoxalase enzymes are glyoxalase I and glyoxalase II (Glo1 and Glo2). PMID: 26552067
24. The GLO1 variations were not the source of association of the BTBD9 locus with restless legs syndrome. PMID: 26298793
25. Glo1 is involved in the Min-U-Sil 5 crystalline silica-induced BEAS-2B cell mitochondrial apoptotic pathway. PMID: 25841781
26. Two classes of the metalloenzyme GlxI exist and vary in their metal dependencies PMID: 25557363
27. GLO1 activity affects the overall burden of carotid artery atherosclerosis. PMID: 24767709
28. individuals with the GLO1 A /E genotype, PON192/QR-RR genotypes and PON55/LM-MM genotypes had a significantly higher risk of cerebral cavernous malformations compared with the other genotypes. PMID: 26122242
29. This study demonstrated that the GLO1 C332 (Ala111) allele confers autism vulnerability by reducing brain glyoxalase activity and enhancing advanced glycation end-products. formation PMID: 25201284
30. This review describes the role of GLO1 in tumor cell proliferation and survival, and the potential of GLO1 as a biomarker for tumor diagnosis and as a target for anticancer drug development. [review] PMID: 25342507
31. Significant differences in the allelic and genotype frequencies of GLO1. PMID: 25407489
32. In ApoE(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation. PMID: 25139743
33. Data show that GlxI is a novel substrate of TG2 and TG2 catalyzes either polyamine conjugation or deamidation depending the presence of polyamines. PMID: 24494193
34. results suggested involvement of accumulated dicarbonyls and/or pentosidine in the pathophysiology of schizophrenia patients carrying Glyoxalase-1 mutations. PMID: 24995521
35. Study demonstrates that GLO1 is a novel metabolic oncogene of the 6p21 amplicon, which promotes tumor growth and aberrant transcriptional signals via regulating cellular metabolic activities for energy production. PMID: 24662817
36. GLO1 lessened inhibitory phosphorylation of eNOS (Thr495) by reducing glycative stress. Study demonstrates that blunting glycative stress prevents the long-term impact of endothelial dysfunction on vascular aging. PMID: 24612481
37. GLO1 is prevailingly expressed in cutaneous neoplasms of higher malignancy and contributes to the progression of squamous cell carcinoma PMID: 25184957
38. Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder PMID: 24671236
39. Suggest Glo1 pathway activation is required for cell proliferation and cell survival of hepatocellular carcinoma cells carrying Glo1 genetic amplification. PMID: 24966916
40. Report association of GLO1 (rs4746) polymorphism with markers of endothelial activation in diabetes mellitus. PMID: 24908234
41. Overexpression of GLO1 in bone marrow cells is sufficient to overcome the defective neovascularization that is characteristic of diabetes. PMID: 24259499
42. Overall, thus Glo1 might be essential for hepatocellular carcinoma progression and can be designated as a potential therapeutic target for hepatocellular carcinoma in the future. PMID: 24158671
43. level by differently inhibiting GI via NF-kappaB.Superoxide anion and hydrogen peroxide induced a diverse apoptosis. PMID: 24002659
44. we provided evidence of the biological plausibility of Glyoxalase 1 polymorphism, either alone or in combination with other ones, all related to oxidative stress control that represents a key event in PCa development and progression. PMID: 24040147
45. GLO1 was the only protein which consistently varied according to the metastatic potentials of SN12C clones. GLO1 was increased in high metastatic cell lines by western blot analysis. PMID: 23982595
46. data suggest a possible association of C332C-genotype of the glyoxalase 1 gene with diabetic neuropathy in type 2 diabetes, supporting the hypothesis that methylglyoxal might be an important mediator of diabetic neuropathy in type 2 diabetes. PMID: 23775136
47. GLO1 expression level in prostate cancer tissues correlates with pathological grade and proliferation rate. PMID: 24105621
48. Data suggest that GLO1 activity is lower in blood (in whole blood assay) in type 1 or type 2 diabetes with painful peripheral diabetic neuropathy as compared to control subjects; Glo1 activity negatively correlates with duration of type 1 diabetes. PMID: 23351995
49. The Ala111Glu glyoxalase gene polymorphism did not have an effect on glyoxalase 1 activity in either the type 1 diabetes mellitus or healthy control group. PMID: 23360186
50. No evidence of an association of RAGE or glyoxalase I single nucleotide polymorphisms with pathological pregnancy. PMID: 22771726
顯示更多

收起更多
蛋白家族：

Glyoxalase I family
數據庫鏈接：

HGNC: 4323

OMIM: 138750

KEGG: hsa:2739

STRING: 9606.ENSP00000362463

UniGene: Hs.268849

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human